for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford BioMedica plc

OXB.L

Latest Trade

769.00GBp

Change

-7.00(-0.90%)

Volume

87,022

Today's Range

746.00

 - 

777.00

52 Week Range

356.73

 - 

860.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

PIRC Recommends A.G. Barr Shareholders To Vote Against Resolution To Approve Remuneration Policy

June 18 (Reuters) - PIRC ::PROXY ADVISORY FIRM PIRC RECOMMENDS A.G. BARR SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO APPROVE REMUNERATION POLICY.PROXY ADVISORY FIRM PIRC RECOMMENDS OXFORD BIOMEDICA SHAREHOLDERS VOTE AGAINST RESOLUTION TO ISSUE SHARES FOR FINANCING DEAL/OTHER CAPITAL INVESTMENT.PROXY ADVISORY FIRM PIRC RECOMMENDS A.G. BARR SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO AUTHORISE SHARE REPURCHASE.PROXY ADVISORY FIRM PIRC RECOMMENDS TRAINLINE SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO AUTHORISE SHARE REPURCHASE.PROXY ADVISORY FIRM PIRC RECOMMENDS TRAINLINE SHAREHOLDERS VOTE AGAINST RESOLUTION TO APPOINT AUDITORS.PROXY ADVISORY FIRM PIRC RECOMMENDS TRAINLINE SHAREHOLDERS VOTE AGAINST RESOLUTION TO ISSUE SHARES FOR FINANCING ACQUISITION/OTHER CAPITAL INVESTMENT.PROXY ADVISORY FIRM PIRC RECOMMENDS MEARS SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO RE-APPOINT GRANT THORNTON UK AS AUDITORS.PROXY ADVISORY FIRM PIRC RECOMMENDS MEARS SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO RE-ELECT DAVID MILES.PROXY ADVISORY FIRM PIRC RECOMMENDS MEARS GROUP SHAREHOLDERS VOTE AGAINST RESOLUTION TO ISSUE SHARES ON FINANCING ACQUISITION/OTHER CAPITAL INVESTMENT.

Oxford Biomedica Announces Proposed Placing To Raise Up To £40 Mln

June 18 (Reuters) - Oxford BioMedica PLC <OXB.L>::OXFORD BIOMEDICA PLC - PROPOSED PLACING OF NEW ORDINARY SHARES.OXFORD BIOMEDICA PLC - PLACING IS PROPOSED TO RAISE UP TO £40 MILLION, BEFORE EXPENSES.OXFORD BIOMEDICA PLC - INTENTION TO CONDUCT A NON-PRE-EMPTIVE PLACING REPRESENTING APPROXIMATELY 6.5% OF COMPANY'S EXISTING ISSUED SHARE CAPITAL.OXFORD BIOMEDICA- NET PROCEEDS OF PLACING TO PROVIDE ADDITIONAL RESOURCES FOR WORK INVOLVED WITH RELATING TO POTENTIAL COVID-19 VACCINE CANDIDATES.OXFORD BIOMEDICA PLC - £5M REVOLVING CREDIT FACILITY WITH A HIGH STREET BANK IS EXPECTED TO BE MADE AVAILABLE TO GROUP IN NEAR TERM.OXFORD BIOMEDICA PLC - INITIAL CLINICAL TRIAL DATA FOR COVID-19 VACCINE (AZD1222) IS EXPECTED DURING Q3 2020.OXFORD BIOMEDICA PLC - IS TARGETING SPIN OUT / OUT-LICENSE OF ONE IN-HOUSE PRODUCT CANDIDATE PRIOR TO YEAR END.OXFORD BIOMEDICA PLC - PRICE PER PLACING SHARE IS 800 PENCE.

Oxford BioMedica Says Sanofi Intends To Return Rights To Certain Ophthalmology Gene Therapy Programmes

June 8 (Reuters) - Oxford BioMedica PLC <OXB.L>::OXFORD BIOMEDICA PLC - UPDATE ON SANOFI OPHTHALMOLOGY PROGRAMMES.OXFORD BIOMEDICA PLC - COLLABORATION AND LICENCE AGREEMENT WITH BIOVERATIV REMAINS UNAFFECTED.OXFORD BIOMEDICA - SANOFI INTENDS TO RETURN TO OXB RIGHTS TO CERTAIN OPHTHALMOLOGY GENE THERAPY PROGRAMMES.OXFORD BIOMEDICA PLC - TIMING OF RETURN OF THESE PROGRAMMES AND OPERATIONAL DETAILS ARE YET TO BE DETERMINED.

Oxford Biomedica Signs Collaboration Agreement With Vaccines Manufacturing and Innovation Centre

June 8 (Reuters) - Oxford BioMedica PLC <OXB.L>::OXFORD BIOMEDICA PLC - SIGNS FIVE YEAR COLLABORATION AGREEMENT WITH VACCINES MANUFACTURING AND INNOVATION CENTRE.OXFORD BIOMEDICA PLC - VMIC WILL PROVIDE MANUFACTURING EQUIPMENT FOR CO TO RAPIDLY EQUIP TWO NEW GMP MANUFACTURING SUITES.OXFORD BIOMEDICA - AGREEMENT WILL PROVIDE SIGNIFICANT ADDITIONAL MANUFACTURING CAPACITY AND ENABLE FURTHER SCALE UP FOR AZD1222 FROM SUMMER OF 2020.OXFORD BIOMEDICA PLC - SUITES COULD ALSO POTENTIALLY BE UTILISED FOR OTHER VIRAL VECTOR VACCINE CANDIDATES.OXFORD BIOMEDICA PLC - VMIC FACILITY IS DUE TO OPEN IN MID-2021, A YEAR AHEAD OF SCHEDULE.

Oxford Biomedica Says Total FY Revenue Excepted To Be C.£65 Million

March 18 (Reuters) - Oxford BioMedica PLC <OXB.L>::OXFORD BIOMEDICA - TOTAL FY REVENUE EXCEPTED TO BE C.£65 MILLION, SLIGHT DECLINE ON PRIOR YEAR DUE TO LOWER MILESTONE AND LICENSING REVENUE.OVERALL OPERATING EBITDA IS EXPECTED TO SHOW A LOW SINGLE DIGIT LOSS IN SECOND HALF.OXFORD - ENTERED INTO MAJOR NEW LICENCE AND 5-YEAR CLINICAL SUPPLY AGREEMENT WITH JUNO THERAPEUTICS FOR INITIALLY FOUR CAR-T AND TCR-T PROGRAMMES.OXFORD CO TO RECEIVE $10 MLN UPFRONT PAYMENT, UP TO $86 MLN IN DEVELOPMENT AND REGULATORY MILESTONES FOR AGREEMENT.

Oxford Biomedica Announces Extension Of Commercial Supply Agreement

Dec 19 (Reuters) - Oxford BioMedica PLC <OXB.L>::OXFORD BIOMEDICA PLC - EXTENSION OF COMMERCIAL SUPPLY AGREEMENT.OXFORD BIOMEDICA PLC - OXFORD BIOMEDICA EXTENDS COMMERCIAL SUPPLY AGREEMENT BY FIVE YEARS FOR MANUFACTURE OF LENTIVIRAL VECTORS.OXFORD BIOMEDICA - TO GET MINIMUM $75 MILLION FROM NOVARTIS OVER NEXT 5 YRS IN MANUFACTURING REVENUE WITH EXTRA UNDISCLOSED PROCESS DEVELOPMENT FEES.OXFORD BIOMEDICA PLC - MID SINGLE DIGIT £M PAYMENT WILL ALSO BE PAID IN MEDIUM TERM AS A FACILITY RESERVATION FEE.OXFORD BIOMEDICA - WILL DEDICATE MANUFACTURING FACILITY TO NOVARTIS WITHIN ITS NEW 7,800M COMMERCIAL MANUFACTURING CENTRE OXBOX, IN OXFORD, UK.OXFORD BIOMEDICA - EXTEND COMMERCIAL SUPPLY AGREEMENT WITH NOVARTIS FOR MANUFACTURE OF LENTIVIRAL VECTORS FOR NOVARTIS CAR-T PORTFOLIO.

Oxford BioMedica Posts H1 Revenue Down 9%

Sept 4 (Reuters) - Oxford BioMedica PLC <OXB.L>::H1 REVENUE FELL 9 PERCENT TO 32.1 MILLION STG.OXFORD BIOMEDICA INTERIM RESULTS.HY REVENUES WERE £32.1 MILLION, A DECREASE OF 9%.EXPECTS, AS PREVIOUSLY OBSERVED, A STRONGER SECOND HALF OF YEAR.CAPEX SPEND IN SECOND HALF OF 2019 WILL CONTINUE AT A HIGHER RATE THAN IN 2018.HY OPERATING LOSS £6.1 MILLION.

Oxford Biomedica Says Novo Holdings Agreed To Invest Up To £53.5 Mln In Group

May 28 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::OXFORD BIOMEDICA - NOVO HOLDINGS A/S AGREED TO INVEST UP TO £53.5 MILLION IN GROUP.OXFORD BIOMEDICA - NOVO HOLDINGS' INVESTMENT IN RETURN FOR NEW ORDINARY SHARES REPRESENTING UP TO 10.1% OF OUTSTANDING SHARES AFTER CAPITAL INCREASE.OXFORD BIOMEDICA PLC - PROCEEDS FROM DEAL WILL BE USED TO REPAY EXISTING DEBT FACILITY WITH OAKTREE CAPITAL MANAGEMENT IN FULL.OXFORD BIOMEDICA - PROCEEDS FROM DEAL WILL ALSO BE USED TO TO FURTHER DEVELOP LENTIVECTOR PLATFORM AND PROPRIETARY PRODUCT PORTFOLIO.

Oxford Biomedica Says Japanese Approval Of Kymriah

March 26 (Reuters) - Oxford BioMedica PLC <OXB.L>::JAPANESE APPROVAL OF KYMRIAH® (TISAGENLECLEUCEL).NOTES AN ANNOUNCEMENT BY NOVARTIS THAT JAPAN'S MINISTRY OF HEALTH, LABOR AND WELFARE (MHLW) HAS APPROVED KYMRIAH.

Oxford Biomedica's FY Gross Income Increased By 72 Pct

March 14 (Reuters) - Oxford BioMedica PLC <OXB.L>::PRELIMINARY RESULTS.FY GROSS INCOME INCREASED BY 72% TO £67.9 MILLION (2017: £39.4 MILLION).FY REVENUE INCREASED BY 78% TO £66.8 MILLION (2017: £37.6 MILLION).FY ADJUSTED OPERATING EXPENSES INCREASED BY 38% TO £31.7 MILLION (2017: £22.9 MILLION).FY OPERATING EBITDA OF £13.4 MILLION (2017: OPERATING EBITDA LOSS OF £1.9 MILLION).YEAR-END INVENTORIES INCREASED DUE ONGOING BIOPROCESSING COMMITMENTS ACROSS 2018 AND INTO 2019 FOR BREXIT PLANNING.GROUP HAS ASSESSED FUTURE IMPACT OF BREXIT ON ITS OPERATIONS TO BE MINOR.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up